Verdiperstat in Amyotrophic Lateral Sclerosis

Overview of attention for article published in JAMA Neurology, February 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

news: 10 news outlets
blogs: 2 blogs
twitter: 16 X users
facebook: 3 Facebook pages

video: 1 YouTube creator
bluesky: 1 Bluesky user
podcasts: 1 podcast

Readers on

mendeley: 32 Mendeley

So far, Altmetric has seen 6 public wall posts from 3 users.

JAMA Neurology, 23 Apr 2025

Treatment with verdiperstat was unlikely to alter disease progression in amyotrophic lateral sclerosis.

JAMA Neurology, 24 Feb 2025

Most viewed in the last 7 days from JAMA Neurology: Results show that in ALS, the use of verdiperstat did not impact the…

JAMA Neurology, 22 Feb 2025

Most viewed in the last 7 days from JAMA Neurology: Results show that in ALS, the use of verdiperstat did not impact the…

JAMA, 17 Feb 2025

From JAMA Neurology: Treatment with verdiperstat was unlikely to alter disease progression in amyotrophic lateral sclerosis. …

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 2 additional Facebook posts.